CVS vs RDGT
CVS Health Corp. and Ridgetech Inc., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | CVS | RDGT |
|---|---|---|
| Revenue | $402.1B | $132.2M |
| Net income | $1.8B | $-1.3M |
| Gross margin | 45.0% | 3.6% |
| Net margin | 0.4% | −0.9% |
| Return on equity | 2.3% | −3.6% |
| Diluted EPS | $1.39 | −$17.21 |
| Dividend / share | $2.66 | · |
| Payout ratio | 192.1% | · |
| Free cash flow | $7.8B | $-1.4M |
| Equity | $75.2B | · |
| Net debt / equity | 0.69× | · |
| Current ratio | 0.84× | 2.31× |
| Revenue CAGR 5y | 8.4% | −0.1% |
| Profit CAGR 5y | −24.4% | · |
CVS bills 3042.2× the revenue of RDGT, and RDGT closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | CVS | RDGT |
|---|---|---|
| FY2025 | $402.1B | $132.2M |
| FY2024 | $372.8B | $120.0M |
| FY2023 | $357.8B | $124.0M |
| FY2022 | $322.5B | $120.2M |
| FY2021 | $292.1B | $164.4M |
| FY2020 | $268.7B | $133.1M |
| FY2019 | $256.8B | $117.3M |
Bottom line
| Fiscal year | CVS | RDGT |
|---|---|---|
| FY2025 | $1.8B | $-1.3M |
| FY2024 | $4.6B | $10.2M |
| FY2023 | $8.3B | $-4.2M |
| FY2022 | $4.3B | $-21.1M |
| FY2021 | $8.0B | $-3.2M |
| FY2020 | $7.2B | $-8.1M |
| FY2019 | $6.6B | $-5.8M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$401,934,836,266 | CVS |
| FY2024 | +$372,689,028,362 | CVS |
| FY2023 | +$357,652,005,947 | CVS |
| FY2022 | +$322,346,800,807 | CVS |
| FY2021 | +$291,946,607,445 | CVS |
| FY2020 | +$268,572,865,367 | CVS |
| FY2019 | +$256,658,672,311 | CVS |
CVS has reported the higher revenue in every one of these 7 fiscal years. The gap has widened since the earliest year compared.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +1.4 pp | CVS |
| FY2024 | −7.3 pp | RDGT |
| FY2023 | +5.8 pp | CVS |
| FY2022 | +18.9 pp | CVS |
| FY2021 | +4.7 pp | CVS |
| FY2020 | +9.0 pp | CVS |
| FY2019 | +8.1 pp | CVS |
The higher net margin has changed hands between CVS and RDGT over this period.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
RDGT's net margin has been more volatile than CVS's over the 7 comparable fiscal years — 7.2 percentage points of standard deviation against 0.8.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between CVS and RDGT over these 7 fiscal years — CVS led in 6 and RDGT in 1.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
RDGT's return on equity has been more volatile than CVS's over the 7 comparable fiscal years — 40.3 percentage points of standard deviation against 3.3.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between CVS and RDGT over these 7 fiscal years — CVS led in 6 and RDGT in 1.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.